Novavax Updates Pediatric COVID-19 Vaccine Trial: What Investors Should Watch
Novavax (NVAX) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Novavax (NVAX) is running a Phase 2/3 trial called “A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in Children 6 Months to < 12 Years of Age.” The goal is to see how well its COVID-19 shot works and how safe it is in young children, a key step if Novavax wants a long term role in the pediatric vaccine market.
The study is testing NVX-CoV2373, a protein based COVID-19 vaccine that uses a Matrix-M adjuvant to boost the immune response. It compares this vaccine with a saline placebo and also looks at booster or variant based shots to see if kids can keep strong protection over time.
The trial is interventional and randomized, meaning children are assigned by chance to get either the vaccine or placebo. It uses a crossover model and triple masking, so participants, caregivers, and study staff do not know who gets what, and the main aim is to prevent COVID-19 by tracking safety and immune responses.
The study started after submission on 2022-07-18, marking Novavax’s move into younger age groups. The trial is now listed as completed, and the latest update on 2026-05-19 signals that new data or analysis has been added even though formal results are not yet posted.
For investors, the update confirms Novavax is still pushing to stay relevant in a crowded COVID-19 field dominated by mRNA players like Pfizer/BioNTech and Moderna. Solid pediatric data could support new approvals or contracts, but the absence of posted results keeps near term stock impact modest and leaves market reaction tied to upcoming disclosures and any guidance from management.
The study remains active in terms of data reporting and has been recently updated, with further information available on the ClinicalTrials portal.
To learn more about NVAX’s potential, visit the Novavax drug pipeline page.
